GOZELLIX Drug Patent Profile
✉ Email this page to a colleague
When do Gozellix patents expire, and when can generic versions of Gozellix launch?
Gozellix is a drug marketed by Telix Innovations and is included in one NDA. There is one patent protecting this drug.
This drug has forty-six patent family members in nineteen countries.
The generic ingredient in GOZELLIX is gallium ga-68 gozetotide. There are sixteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the gallium ga-68 gozetotide profile page.
DrugPatentWatch® Generic Entry Outlook for Gozellix
There have been ten patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for GOZELLIX?
- What are the global sales for GOZELLIX?
- What is Average Wholesale Price for GOZELLIX?
Summary for GOZELLIX
| International Patents: | 46 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Patent Applications: | 15 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for GOZELLIX |
| What excipients (inactive ingredients) are in GOZELLIX? | GOZELLIX excipients list |
| DailyMed Link: | GOZELLIX at DailyMed |
US Patents and Regulatory Information for GOZELLIX
GOZELLIX is protected by one US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Telix Innovations | GOZELLIX | gallium ga-68 gozetotide | POWDER;INTRAVENOUS | 219592-001 | Mar 20, 2025 | RX | Yes | Yes | 11,027,031 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for GOZELLIX
When does loss-of-exclusivity occur for GOZELLIX?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 15309187
Estimated Expiration: ⤷ Start Trial
Patent: 15309188
Estimated Expiration: ⤷ Start Trial
Patent: 20220193
Estimated Expiration: ⤷ Start Trial
Patent: 20220194
Estimated Expiration: ⤷ Start Trial
Patent: 22202346
Estimated Expiration: ⤷ Start Trial
Patent: 22202439
Estimated Expiration: ⤷ Start Trial
Patent: 24205118
Estimated Expiration: ⤷ Start Trial
Belgium
Patent: 21191
Estimated Expiration: ⤷ Start Trial
Brazil
Patent: 2017003578
Estimated Expiration: ⤷ Start Trial
Patent: 2017003710
Estimated Expiration: ⤷ Start Trial
Patent: 2021017474
Estimated Expiration: ⤷ Start Trial
Canada
Patent: 58471
Estimated Expiration: ⤷ Start Trial
Patent: 58475
Estimated Expiration: ⤷ Start Trial
Patent: 67294
Estimated Expiration: ⤷ Start Trial
China
Patent: 6659806
Estimated Expiration: ⤷ Start Trial
Patent: 6794265
Estimated Expiration: ⤷ Start Trial
Denmark
Patent: 85911
Estimated Expiration: ⤷ Start Trial
European Patent Office
Patent: 85911
Estimated Expiration: ⤷ Start Trial
Patent: 85912
Estimated Expiration: ⤷ Start Trial
Patent: 62025
Estimated Expiration: ⤷ Start Trial
Patent: 62026
Estimated Expiration: ⤷ Start Trial
France
Patent: C1028
Estimated Expiration: ⤷ Start Trial
Hungary
Patent: 53971
Estimated Expiration: ⤷ Start Trial
Israel
Patent: 0735
Estimated Expiration: ⤷ Start Trial
Patent: 0736
Patent: ערכה עבור התוויה רדיואקטיבית עם ga68 המכיל מעכב מתכת (Kit for radiolabelling with 68ga comprising a metal inhibitor)
Estimated Expiration: ⤷ Start Trial
Japan
Patent: 43343
Estimated Expiration: ⤷ Start Trial
Patent: 52622
Estimated Expiration: ⤷ Start Trial
Patent: 17526745
Patent: 金属阻害剤
Estimated Expiration: ⤷ Start Trial
Patent: 17530188
Patent: 放射標識用キット
Estimated Expiration: ⤷ Start Trial
Mexico
Patent: 9367
Patent: KIT PARA MARCAJE RADIACTIVO CON GALIO 68 (68GA) QUE COMPRENDE UN INHIBIDOR DE METAL. (KIT FOR RADIOLABELLING WITH 68GA COMPRISING A METAL INHIBITOR)
Estimated Expiration: ⤷ Start Trial
Patent: 8098
Patent: MONO-, DI-, O POLISACARIDO USADO COMO INHIBIDOR DE METAL EN LA PREPARACION DEL AGENTE ENFOCADO FUNCIONALIZADO CON QUELATO GALIO 68 (68GA). (MONO-, DI- OR POLYSACCHARIDE USED AS METAL INHIBITOR IN THE PREPARATION OF 68GA-CHELATE-FUNCTIONALIZED TARGETING AGENT)
Estimated Expiration: ⤷ Start Trial
Patent: 17002361
Patent: MONO-, DI-, O POLISACARIDO USADO COMO INHIBIDOR DE METAL EN LA PREPARACION DEL AGENTE ENFOCADO FUNCIONALIZADO CON QUELATO GALIO 68 (68GA). (MONO-, DI- OR POLYSACCHARIDE USED AS METAL INHIBITOR IN THE PREPARATION OF 68GA-CHELATE-FUNCTIONALIZED TARGETING AGENT.)
Estimated Expiration: ⤷ Start Trial
Patent: 17002362
Patent: KIT PARA MARCAJE RADIACTIVO CON GALIO 68 (68GA) QUE COMPRENDE UN INHIBIDOR DE METAL. (KIT FOR RADIOLABELLING WITH 68GA COMPRISING A METAL INHIBITOR.)
Estimated Expiration: ⤷ Start Trial
New Zealand
Patent: 9291
Patent: Kit for radiolabelling with 68ga comprising a metal inhibitor
Estimated Expiration: ⤷ Start Trial
Patent: 9293
Patent: Mono-, di- or polysaccharide used as metal inhibitor in the preparation of 68ga-chelate-functionalized targeting agent
Estimated Expiration: ⤷ Start Trial
Poland
Patent: 85911
Estimated Expiration: ⤷ Start Trial
Portugal
Patent: 85911
Estimated Expiration: ⤷ Start Trial
Russian Federation
Patent: 24894
Estimated Expiration: ⤷ Start Trial
Patent: 25627
Estimated Expiration: ⤷ Start Trial
Patent: 17109582
Patent: ИНГИБИТОР МЕТАЛЛОВ (METAL INHIBITOR)
Estimated Expiration: ⤷ Start Trial
Patent: 17109583
Patent: НАБОР ДЛЯ МЕЧЕНИЯ РАДИОАКТИВНЫМИ ИЗОТОПАМИ (RADIO-ISOTOPE LABELING KIT)
Estimated Expiration: ⤷ Start Trial
South Africa
Patent: 1702152
Patent: KIT FOR RADIOLABELLING WITH 68GA COMPRISING A METAL INHIBITOR
Estimated Expiration: ⤷ Start Trial
Spain
Patent: 55991
Estimated Expiration: ⤷ Start Trial
Patent: 56030
Estimated Expiration: ⤷ Start Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering GOZELLIX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2015309187 | ⤷ Start Trial | |
| Australia | 2015309188 | ⤷ Start Trial | |
| Australia | 2020220193 | ⤷ Start Trial | |
| Australia | 2020220194 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch